Edward Stelmakh sold $19k of OPRX
Chief Finance & Strat Officer at OptimizeRx Corp. 1,388 shares at an average of $13.51, traded Dec 19, 2025, filed Dec 22, 2025.
Score components
- +22RoleCFO
- 0Trade size$19k at market
- 0Share of holdings soldSold 1.1% of holdings
- 0ClusterNo other insider selling within 14 days
- -15Exercise and sellShares came from an option exercise in the same filing
What happened after comparable sells
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
This signal so far: 1m -12.3%, 3m -51.6%, 6m -64.8%.
Price around the trade, and since
From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™
Rows in this filing
Every transaction in Form 4 0001628280-25-058413, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Dec 19, 2025 | MOption exercise Common Stock | +5,237 | $0.00 | $0 | 128,218 | Dec 22, 2025 |
| Dec 19, 2025 | SOpen-market sale Common Stock | -1,388 | $13.51 | $19k | 126,830 | Dec 22, 2025 |
| Dec 19, 2025 | MOption exercise Restricted Stock Unitsderivative | -5,237 | $0.00 | $0 | 5,237 | Dec 22, 2025 |
Related signals
Other insiders at OptimizeRx Corp and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 15Weak | OPRXsell OptimizeRx Corp | Stephen L Silvestro Chief Executive Officer | $30k 1,620 shares | -1% | |
| 32Weak | OPRXsell OptimizeRx Corp | Patrick D Spangler director | $194k 11,120 shares | -20% | |
| 35Weak | OPRXbuy OptimizeRx Corp | William J Febbo CEO | $100k 20,000 shares | +3% | |
| 12Weak | OptimizeRx Corp | Marion Odence-Ford General Counsel and CCO | $61k 4,000 shares | -26% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.